Clinical Focus

  • Nuclear Medicine
  • Theranostics
  • Targeted Radionuclide Therapy
  • PET Imaging
  • Nuclear Cardiology
  • Molecular Imaging

Academic Appointments

Honors & Awards

  • Sipra and Gopal Saha Scholarship award, SNMMI (6/2023)
  • Resident of the month, Icahn School of Medicine at Mount Sinai (4/2022 and 2/2023)
  • Future Leaders Academy, SNMMI (1/2023)

Boards, Advisory Committees, Professional Organizations

  • In-training & Early Career Professionals Committee, Member, SNMMI (2023 - Present)
  • Procedure Standards Committee, Member, SNMMI (2023 - Present)
  • Mount Sinai Hospital Medical Board, Resident Representative, The Mount Sinai Hospital (2023 - 2024)
  • Alternate Delegate for the AMA Resident & Fellows Section, SNMMI (2023 - Present)
  • Nuclear Medicine Residents Organization, Board Member, ACNM - NMRO (2022 - 2024)
  • Member, ASNC (2023 - Present)
  • Member, ARRS (2023 - Present)
  • Member, EANM (2022 - Present)
  • Member, RSNA (2021 - Present)
  • Member, SNMMI (2021 - Present)

Professional Education

  • Residency: Rutgers New Jersey Medical School Dept of General Surgery (2020) NJ
  • Board Certification: American Board of Nuclear Medicine, Nuclear Medicine (2024)
  • Residency, Icahn School of Medicine at Mount Sinai - Nuclear Medicine and Molecular Imaging, NY (2024)
  • Fellowship, Texas Tech University Health Sciences Center - Burn Surgery and Wound Care, TX (2021)
  • Residency, Rutgers, New Jersey Medical School - General Surgery, NJ (2020)
  • Internship, Morristown Medical Center, Atlantic Health System - General Surgery, NJ (2019)
  • Research Fellowship, The Cleveland Clinic - Colorectal Surgery, OH (2018)
  • Medical Education, Universita' degli Studi di Bologna, Scuola di Medicina e Chirurgia, Italy (2016)

Contact

  • Clinical (Primary)  Nuclear Medicine Clinic 300 Pasteur Dr Rm H2233 Stanford, CA 94305 (650) 498-5047 (fax)

Additional Clinical Info

Additional Info

Clinical Trials

  • Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting

    This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal adenocarcinoma. Following screening, using a standardized administration protocol and dose, participants will undergo \[¹⁸F\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \[¹⁸F\]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \[¹⁸F\]FAPI-74 PET/CT.

    View full details